Post-hoc analysis of 3-year data from the LipiDiDiet clinical trial reveals slower clinical decline in participants receiving a multinutrient supplement


The LipiDiDiet study is a 6-year, double-blind, multi-center randomised clinical trial of a multinutrient supplement, Fortasyn Connect, compared to a control product, for people with prodromal Alzheimer’s disease (AD)/mild cognitive impairment. In a newly-published, post-hoc analysis of 3-year data from the trial, researchers show that participants who take Fortasyn connect exhibit slower clinical decline based on the AD Composite Score scale (ADCOMS). LipiDiDiet is a long-term trial that gives participants the opportunity to continue taking Fortasyn Connect for up to 6 years. Fortasyn Connect, also known as Souvenaid, is a commercially-available multinutrient supplement that contains a number of vitamins and minerals. A 24-month analysis of LipiDiDiet data showed improvements on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale, but no improvement on the Neuropsychological test battery (NTB).

This new post-hoc analysis aimed to assess the value of continuing with Fortasyn Connect for a longer period of time, using a composite scale that assesses both cognitive and functional domains. They complemented these analyses with additional statistical tests that evaluated the totality of data from different clinical trial outcomes. The analysis included 67 participants who completed 36 months on the LipiDiDiet trial, 39 of whom took the Fortasyn Connect supplement. All the outcome measures showed a statistically significant benefit for supplementation, with an estimated 38% slowing of clinical decline in a hierarchical analysis including the NTB, CDR-SB, and structural measures of brain atrophy. Read the full article, here: